



THOMSON REUTERS



FOR IMMEDIATE RELEASE

## NEWS RELEASE

### CONTACTS

Laura Cruz  
Tenor Communications for NVCA  
1.917.406.7517  
laura@tenorcom.com

Lauren Herman  
Thomson Reuters  
1.646.223.5985  
lauren.herman@thomsonreuters.com

### **VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q2'2013 WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000**

#### **M&A Volume Declines to Lowest Quarterly Level Since 2009**

**New York, New York, July 1, 2013** – Twenty-one venture-backed initial public offerings (IPOs) raised \$2.1 billion during the second quarter of 2013, more than double the volume and dollars compared to the first quarter of this year, according to the Exit Poll report by Thomson Reuters and the National Venture Capital Association (NVCA). This quarter also saw the highest number of biotechnology venture-backed IPOs since the third quarter of 2000. For the second quarter of 2013, 84 venture-backed M&A deals were reported, 15 which had an aggregate deal value of \$3.0 billion. This represents a 53 percent decrease in volume from the second quarter of 2012.

“We have been predicting an IPO pickup in the second half of 2013 and it appears as if this momentum has begun, driven by the strong biotechnology offerings,” said Mark Heesen, president of the NVCA. “We are hopeful that this positive trend will not be impacted by negative externalities in the second half of the year, as has been the case over the last several years. While on the surface, the low acquisitions volume thus far in 2013 could appear problematic, our market intelligence is telling us that there is a great deal of in-bound interest for venture backed targets, suggesting that these companies are holding out for better pricing from strategic buyers. With an improving IPO market, this situation will only improve for our companies.”



Quarter/Year	Total M&A Deals	M&A Deals with Disclosed Values	*Total Disclosed M&A Value (\$M)	*Average M&A Deal Size (\$M)	**Number of IPO's	Total Offer Amount (\$M)	Average IPO Offer Amount (\$M)
<b>2008</b>	<b>422</b>	<b>134</b>	<b>16,236.9</b>	<b>121.2</b>	<b>7</b>	<b>765.0</b>	<b>109.3</b>
2009-1	81	19	830.5	43.7	0	0.0	0.0
2009-2	79	15	1,982.4	132.2	7	997.6	142.5
2009-3	100	30	2,224.3	74.1	2	522.5	261.3
2009-4	100	45	7,327.7	162.8	4	459.7	114.9
<b>2009</b>	<b>360</b>	<b>109</b>	<b>12,364.9</b>	<b>113.4</b>	<b>13</b>	<b>1,979.8</b>	<b>152.3</b>
2010-1	149	36	4,945.1	137.4	8	921.9	115.2
2010-2	109	30	2,681.4	89.4	18	1,548.4	86.0
2010-3	141	36	4,140.9	115.0	18	2,061.5	114.5
2010-4	145	47	5,932.8	126.2	26	3,242.6	124.7
<b>2010</b>	<b>544</b>	<b>149</b>	<b>17,700.3</b>	<b>118.8</b>	<b>70</b>	<b>7,774.4</b>	<b>111.1</b>
2011-1	138	51	5,966.8	117.0	14	1,526.9	109.1
2011-2	95	37	6,202.3	167.6	21	5,883.5	280.2
2011-3	141	43	6,934.5	161.3	5	475.9	95.2
2011-4	124	38	4,989.6	131.3	11	2,803.2	254.8
<b>2011</b>	<b>498</b>	<b>169</b>	<b>24,093.2</b>	<b>142.6</b>	<b>51</b>	<b>10,689.5</b>	<b>209.6</b>
2012-1	113	28	3,671.0	131.1	19	1,682.8	88.6
2012-2	122	34	6,304.4	185.4	12	17,227.9	1435.7
2012-3	124	37	8,437.6	228.0	10	1,140.7	114.1
2012-4	120	29	3,582.4	123.5	8	1,408.4	176.1
<b>2012</b>	<b>479</b>	<b>128</b>	<b>21,995.5</b>	<b>171.8</b>	<b>49</b>	<b>21,459.9</b>	<b>438.0</b>
2013-1	86	10	984.3	98.4	8	716.9	89.6
2013-2	<b>84</b>	<b>15</b>	<b>2,955.6</b>	<b>197.0</b>	21	2,142.5	102.0
<b>2013</b>	<b>170</b>	<b>25</b>	<b>3,939.9</b>	<b>157.6</b>	<b>29</b>	<b>2,859.4</b>	<b>98.6</b>

Source: Thomson Reuters & National Venture Capital Association

\*Only accounts for deals with disclosed values

\*\*Includes all companies with at least one U.S. VC investor that trade on U.S. exchanges, regardless of domicile.

### IPO Activity Overview

There were 21 venture-backed IPOs valued at \$2.1 billion in the second quarter of 2013. By number of deals, quarterly volume more than doubled from the first quarter of this year and registered a 75 percent increase compared to the number of deals listed during the second quarter of 2012.

Led by the biotechnology sector, 13 of the 21 offerings during the quarter were Life Sciences IPOs representing 62 percent of the total issues for the quarter. With 11 biotechnology offerings in the second quarter, this marks the strongest quarter for listings in the sector since the third quarter of 2000, when 13 companies went public.



By location, 20 of the quarter's 21 IPOs were from U.S.-based companies. Prosensa BV, a Netherlands-based biopharmaceutical company, raised \$78 million on the NASDAQ stock exchange on June 28<sup>th</sup>.

In the largest IPO of the quarter, Tableau Software LLC (DATA), a Seattle, Washington-based provider of analytics and data visualization software, raised \$292 million and began trading on the New York Stock Exchange on May 16<sup>th</sup>. The company is currently trading nearly 80 percent above its \$31 offering price.

		Q2 2013	
Industry		*Number of Venture-Backed IPO's in the U.S.	Total Venture-Backed Offering Size (\$M)
Information Technology	Computer Software and Services	3	479.5
	Communications and Media	3	432.4
	Internet Specific	2	167.6
		<b>8</b>	<b>1,079.5</b>
Life Sciences	Biotechnology	11	1,003.8
	Medical/Health	2	70.9
		<b>13</b>	<b>1,074.7</b>
<b>TOTAL</b>		<b>21</b>	<b>2,142.5</b>

**Source: Thomson Reuters & National Venture Capital Association**

\*Includes all companies with at least one U.S. VC investor that trade on U.S. exchanges, regardless of domicile

During the second quarter of 2013, 14 companies listed on the NASDAQ stock exchange and six companies listed on the New York Stock Exchange. One company listed over-the-counter. All of this quarter's biotechnology IPOs listed on the NASDAQ, while all of this quarter's internet specific IPOs listed on the New York Stock Exchange.

Fifteen of the 21 companies brought to market this quarter are currently trading above their offering price. There are 39 venture-backed companies currently filed publicly for IPO with the SEC. This figure does not include confidential registrations filed under the JOBS Act, where many observers believe the majority of venture-backed companies now file.

**Mergers and Acquisitions Overview**

As of June 28<sup>th</sup>, 84 venture-backed M&A deals were reported for the second quarter of 2013, 15 which had an aggregate deal value of \$3.0 billion. The average disclosed deal value was \$197.0 million, more than double the average deal size registered during the first quarter of 2013.

The information technology sector led the venture-backed M&A landscape with 69 of the 83 deals of the quarter and had a disclosed total dollar value of \$1.9 billion. Within this sector, Computer Software and Services and Internet Specific deals accounted for the bulk of the targets with 35 and 20 transactions, respectively, across these sector subsets.



		Q2		
Industry		Number of Venture-Backed M&A deals	Number of Venture-Backed M&A deals with a disclosed value	Total Disclosed Venture-Backed Deal Value (\$M)
<b>Information Technology</b>	Computer Software and Services	35	2	195.0
	Internet Specific	20	2	1,108.5
	Communications and Media	4	1	30.0
	Computer Hardware	2	2	136.7
	Semiconductors/Other Elect.	8	3	416.8
		<b>69</b>	<b>10</b>	<b>1,887.0</b>
<b>Life Sciences</b>	Medical/Health	6	1	23.6
	Biotechnology	5	4	1,045.0
		<b>11</b>	<b>5</b>	<b>1,068.6</b>
<b>Non-High Technology</b>	Consumer Related	2	0	0.0
	Industrial/Energy	1	0	0.0
	Other Products	1	0	0.0
		<b>3</b>	<b>0</b>	<b>0.0</b>
<b>TOTAL</b>		<b>83</b>	<b>15</b>	<b>2,955.6</b>

Source: Thomson Reuters & National Venture Capital Association

The largest venture-backed M&A transaction during the second quarter was in the Internet specific sector, with Yahoo! Inc's \$1.1 billion purchase of Tumblr, Inc, a New York-based social networking publishing platform. The Tumblr acquisition was Yahoo! Inc's fourth acquisition of a U.S. venture-backed company this year. Astrazeneca PLC's \$560 million (excluding earnout) acquisition of Redwood City, California-based Pearl Therapeutics Inc, a developer of therapies for chronic respiratory diseases ranked as the second largest venture-backed M&A deal during the quarter.

Deals bringing in the top returns, those with disclosed values greater than four times the venture investment, accounted for 40 percent of the total disclosed transactions during second quarter of 2013, a marked increase compared to the first quarter of this year. Venture-backed M&A deals returning less than the amount invested accounted for 20 percent of the quarterly total.



**Analysis of Transaction Values versus Amount Invested**

Relationship between transaction value and investment	Q1 13 M&A**	Q2 13 M&A**
Deals where transaction value is less than total venture investment	1	3
Deals where transaction value is 1-4x total venture investment	9	6
Deals where transaction value is 4x-10x total venture investment	0	6
Deals where transaction value is greater than 10x venture investment	0	0
<b>Total Disclosed Deals</b>	<b>10</b>	<b>15</b>

Source: Thomson Reuters & National Venture Capital Association

\*\* Disclosed deals that do not have a disclosed total investment amount are not included

**About Thomson Reuters**

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to <http://thomsonreuters.com>.

**About National Venture Capital Association**

Venture capitalists are committed to funding America's most innovative entrepreneurs, working closely with them to transform breakthrough ideas into emerging growth companies that drive U.S. job creation and economic growth. As the voice of the U.S. venture capital community, the National Venture Capital Association (NVCA) empowers its members and the entrepreneurs they fund by advocating for policies that encourage innovation and reward long-term investment. As the venture community's preeminent trade association, NVCA serves as the definitive resource for venture capital data and unites its nearly 400 members through a full range of professional services. For more information about the NVCA, please visit [www.nvca.org](http://www.nvca.org).